Related Experiment Videos
Supratherapeutic response to ezetimibe administered with cyclosporine
Sheri L Koshman1, Lucille D Lalonde, Ilene Burton
1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
The Annals of Pharmacotherapy
|July 21, 2005
Summary
Heart transplant patients on cyclosporine may experience excessive LDL cholesterol reduction with ezetimibe. Lower starting doses and close monitoring are recommended to manage this drug interaction safely.
Area of Science:
- Cardiology
- Pharmacology
- Transplantation Medicine
Background:
- Hyperlipidemia is prevalent in heart transplant recipients.
- Achieving target lipid levels is crucial for long-term outcomes.
- Combination therapy with statins and ezetimibe is a common strategy.
Observation:
- A heart transplant patient on cyclosporine experienced a significant drop in LDL cholesterol (LDL-C) after initiating ezetimibe.
- The patient's LDL-C levels decreased by 60% to 51 mg/dL on 10 mg/day ezetimibe and atorvastatin.
- Reducing ezetimibe to 5 mg/day resulted in LDL-C levels of 57 mg/dL.
Findings:
- A supratherapeutic response to ezetimibe was observed in a patient receiving cyclosporine.
- This interaction likely stems from a pharmacokinetic interplay between ezetimibe and cyclosporine, potentially affecting glucuronidation.
- Unpublished data indicate a substantial increase in ezetimibe exposure when coadministered with cyclosporine.
Implications:
- Ezetimibe should be initiated at a reduced dose (e.g., 5 mg/day) in heart transplant patients taking cyclosporine.
- Careful monitoring of lipid levels is essential when combining these medications.
- This case highlights the need for cautious prescribing and dose titration to avoid adverse events.